

Supplementary Table S3. Clinical characteristics of a selected cohort of patients treated with anti-EGFR monoclonal antibodies and displaying KRAS wild type status.

SAMPLE	AGE	SEX	TUMOR SITE	THERAPY		RESPONSE		MOLECULAR ANALYSIS										
								Line	Protocol	Best	PFS	IHC (HercepTest)	HER2		KRAS		BRAF	
													HER2/CEP17	FISH	HER2/Cell	Primary	Metastasis	Primary
1	81	F	colon	3rd	panitumumab	PD	NA	3+**	>4**	>14**	NA	WT	WT	WT	WT			
2	40	F	colon	4th	panitumumab	PD	NA	0*/0**			WT	WT	WT	WT				
3	64	M	colon	5th	panitumumab	PD	NA	1+/2+ focal **	1.6 (18%) **	4.2**	WT	WT	WT	WT				
4	64	M	rectum	3rd	panitumumab	PD	NA	2+ *	1.13 *	2.39 *	WT	NA	WT	NA				
5	69	F	rectum	3rd	cetuximab + irinotecan	PD	NA	0**			WT	WT	WT	WT				
6	61	F	colon	3rd	panitumumab	PD	NA	3+*	>3 *	>6 *	WT	NA	WT	NA				
7	57	F	rectum	3rd	panitumumab	PD	NA	1+*			WT	NA	WT	NA				
5	72	M	colon	3rd	panitumumab	PD	NA	0*			WT	NA	WT	NA				
9	55	M	colon	3rd	cetuximab + irinotecan	PD	NA	0*			WT	NA	WT	NA				
10	75	F	colon	1st	cetuximab	PD	NA	0*			WT	NA	WT	NA				
11	77	M	colon	1st	cetuximab	PD	NA	1*			WT	NA	WT	NA				
12	76	F	colon	1st	cetuximab	PD	NA	0*			WT	NA	WT	NA				
13	58	M	rectum	4th	panitumumab	PD	NA	0*/1+**			WT	NA	WT	NA				
14	72	M	colon	1st	cetuximab	PD	NA	0*			WT	NA	WT	NA				
15	41	M	colon	3rd	cetuximab + irinotecan	PD	NA	1+*			WT	NA	WT	NA				
16	56	F	colon	3rd	cetuximab + irinotecan	PD	NA	0*/0**			NA	WT	NA	WT				
17		F	rectum	3rd	panitumumab + irinotecan	SD	115	3+*/3+**	9,02**	12.07**	NA	WT	NA	WT				
18	86	M	colon	3rd	panitumumab	PR	169	0*			WT	WT	WT	WT				
19	56	M	colon	3rd	panitumumab + irinotecan	PR	103	0*			WT	NA	WT	NA				
20	46	F	colon	4th	panitumumab	PR	209	2+*/2+**	1,06**	1,76**	WT	WT	WT	WT				
21	57	M	colon	2nd	cetuximab + irinotecan	PR	386***	1+*			WT	WT	WT	WT				
22	59	M	colon	4th	cetuximab + irinotecan	PR	144	0*			WT	WT	WT	WT				

23	60	M	rectum	3rd	cetuximab + irinotecan	PR	665	0**			WT	WT	WT	WT
24	67	M	colon	3rd	cetuximab + irinotecan	PR	303	2+ focal**	11,7 (49%)**	21**	NA	WT	NA	WT
25	70	M	colon	3rd	panitumumab	PR	233	1+*			WT	WT	WT	WT
26	46	M	colon	3rd	panitumumab	PR	383	0*/0**			WT	WT	WT	WT
27	50	M	colon	3rd	panitumumab	SD	204	0**			WT	WT	WT	WT
28	71	M	colon	2nd	cetuximab + irinotecan	SD	232	1+*			WT	NA	WT	NA
29	55	F	colon	3rd	cetuximab + irinotecan	SD	196	0**			NA	WT	NA	WT
30	76	M	rectum	4th	panitumumab	SD	249	0**			WT	NA	WT	NA
31	61	M	rectum	4th	panitumumab	SD	189	1+*			WT	WT	WT	WT

Highlighted in yellow are cases with positive (3+) HercepTest and homogeneous HER2 amplification

\* Analysis was executed on the primary tumor  
\*\* Analysis was executed on the metastatic lesion  
\*\*\* patient is still maintainig response  
NA, not analyzed  
PFS, progression-free survival